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An evaluation of the second round of faecal occult blood (FOB) screening in the English site of the UK Colorectal Cancer Screening
Pilot (comprising the Bowel Cancer Screening Pilot based in Rugby, general practices in four Primary Care Trusts, and their associated
hospitals) was carried out. A total of 127746 men and women aged 50–69 and registered in participating general practices were
invited to participate. In all, 15.9% were new invitees not included in the previous round. A total of 52.1% of invitees returned a
screening kit. Uptake varied with gender, age, and level of deprivation; was lower than in the first round (51.9 vs 58.5% Po0.0001),
but was high (81.1%) in those who had participated in the first round with a negative result. Test positivity was 1.77%, significantly
higher than in the first round, and the detection rate of neoplasia similar (5.67 per 1000), resulting in a lower positive predictive value.
The sensitivity of FOBt in the first round was estimated as 57.7–64.4%. There was a significant impact on workload, particularly on
endoscopy services. The cancer detection rate (0.94 per 1000) was lower than in the first round. Effort will be required to minimise
inequalities in uptake, and to ensure adequate capacity of endoscopy services.
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Colorectal cancer is a significant public health burden in the UK,
and remains the most common internal malignancy (Wild et al,
2006). Randomised controlled trials have demonstrated that
colorectal cancer mortality can be reduced by screening using
the faecal occult blood test (FOBt) (Towler et al, 1998). In the light
of this, a Pilot was established in the UK in 2000 to examine the
feasibility of population-based screening for colorectal cancer. An
evaluation of the first round of this Pilot has been reported
previously (UK Colorectal Cancer Screening Pilot Evaluation
Team, 2003; UK Colorectal Cancer Screening Pilot Group, 2004),
and a national programme of screening began in England in 2006
and is being rolled out over several years (NHS Cancer Screening
Programmes website). This paper reports on an evaluation of the
second round of the Pilot in England (Weller et al, 2006); it
provides detailed estimates of key outcome measures, including
uptake of FOBt and colonoscopy, test positivity and detection rates
of neoplasia, and a further analysis of the workforce and health
service impact of bowel cancer screening.
MATERIALS AND METHODS
Screening pilot
The first round of the Pilot was conducted at two sites: the West
Midlands in England and Tayside, Grampian, and Fife in Scotland.
This evaluation of the second round includes data from the English
site only. Men and women, aged 50–69 years inclusive, registered
at general practices in Coventry Teaching Primary Care Trust
(PCT), North Warwickshire PCT, Rugby PCT, and South
Warwickshire PCT were eligible; however, due to competing
service priorities, South Warwickshire PCT withdrew from the
Pilot shortly after the commencement of the second round (only
people in two practices in the PCT were invited). The policy was to
invite people who would become 50 years of age during the year,
and so in both rounds, there are a number of people aged 49 years
of age. People aged 70 years or older who were registered with
general practices in the Pilot area were able to request a kit by
contacting the screening unit – strategies for this age group being
made aware of the Pilot included information materials in doctors’
surgeries, and receiving information from a spouse or other
household member.
The English Colorectal Cancer Screening Pilot was administered
from the Bowel Cancer Screening Unit (the screening unit) at the
Hospital of St Cross in Rugby, which sent out invitations with
Hema Screen test kits, comprising a card with six spots. Kits were
returned to the laboratory; after testing (Phase 1 of screening) they
could be negative, weak-positive (one–four spots), strong-positive
(five–six spots) or inadequate. If the result was negative, the
person was informed and no further action taken. If the result was
weak-positive or inadequate, the person was sent another kit
(Phase 2). Test-negative individuals from Phase 2 were sent a
further kit (Phase 3). All those who had either a strong positive
result at Phase 1 or returned any positive test at either of the two
later phases were deemed to have a positive FOBt outcome and
referred.
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screening unit with a screening nurse who provided information
and answered their questions. Bookings for screening nurse
appointments and any investigations required (the standard
follow-up for a FOBt-positive result was colonoscopy at the
nearest endoscopy unit) were also arranged at the screening unit.
Screening for the second round began on 10 February 2003 and
the last invitations were sent out on 9 November 2004. It was
intended that the second round would take place at an interval of
2 years after the first round; however, there was a delay of 5
months before the start of the second round, due to programming
and management constraints – consequently the median time
between invitations was 28 months.
Analyses of data
Routine individual-based data were extracted from the Pilot
site database in June 2005. Additional information on the
Index of Multiple Deprivation (IMD) and on ethnicity were
linked to individuals using postcodes (Census Dissemination Unit
website; Indices of Deprivation, 2004 website). Data on bowel
cancers in people included in the first and/or second rounds were
obtained from West Midlands Cancer Intelligence Unit, to identify
cancers occurring in the interval between screening rounds. Data
from the first and second rounds were linked by matching on NHS
number and month/year of birth, to categorise people in the
second round according to their screening experience in the first
round.
To enable a valid comparison to be made between the two
rounds, analyses were conducted on restricted populations from
both rounds, including only people in those GP practices who were
included in both rounds. We also excluded people aged over 70,
except for analyses looking at self-referrals, and people participa-
ting in a trial of an immunological test in the second round
(n¼5122). Logistic regression was used to investigate associations
between the demographic and ethnic variables and measures of
uptake and positivity. Multivariate analyses including all demo-
graphic factors have been used to produce odds ratios of estimated
effects adjusted for all other factors.
The test sensitivity of FOBt screening in the first round was
estimated using the proportional incidence method (Day, 1985).
Interval cancers included were those diagnosed within 2 years of a
negative FOBt outcome, and before the date of any subsequent
invitation; underlying incidence was estimated using both
incidence rates for England in 2001 and those for West Midlands
for 1998–2000. Cancers of the anus and anal canal were excluded
from both the interval cancers and incidence rates. More details of
the methods are given elsewhere (UK Colorectal Cancer Screening
Pilot Evaluation Team, 2003).
Impact evaluation
Activity data were used to examine any changes in Pilot-generated
workload between the two rounds of screening; workload data on
pathology, colonoscopy, radiology and surgical activity data were
obtained from the first and second round Pilot databases. These
were related to the total (unrestricted) population invited, but
excluding South Warwickshire. In addition, screening activity was
compared with total activity data obtained from each hospital.
These data were supplemented by semi-structured interviews, held
between December 2004 and December 2005, with key staff
(endoscopy unit managers, colonoscopists and surgeons, colo-
rectal cancer nurse specialists, pathologists, pathology laboratory
managers, hospital managers, and screening unit staff). A general
thematic analysis was undertaken using an iterative approach with
analysis beginning after the first interviews to allow emerging
themes to be explored in subsequent interviews.
RESULTS
There were 127746 invitees in the restricted second round
population; 15.9% of people were new invitees, of whom 81.0%
were aged 49–51 years. The proportion of people below age 55
years was slightly lower in the second round than in the first (30.5
vs 33.0%). The distributions of IMD were similar in both rounds,
but there were a slightly higher proportion of people in ethnic
minorities in the second round.
Uptake
FOB test uptake Of the 127746 people invited, 52.1% (66541)
(95% CI: 51.8–52.4) returned a screening kit. Excluding from the
denominator those tests returned by the post office (n¼2185) and
people whose screening episode was closed for one of several
reasons (recent colonoscopy, moved from area, under treatment
for bowel problems, deceased) (n¼3504), the response rate was
54.5% (66541/122057).
Uptake (Table 1), defined as the proportion of those invited who
returned an adequate kit in response to the invitation, was 51.9%
(66264/127746) (95% CI: 51.6–52.1). This was lower than first
round uptake (58.5% Po0.0001); this was true across all categories
of the demographic variables (gender, age and deprivation). If the
categories described above are excluded from the denominators,
the uptake was 54.3% (66264/122057) and 60.6% (76152/125648)
in the second and first rounds respectively.
Rates of return of inadequate kits were low; only 277 (0.4%) of
those responding to the invitation failed to return an adequate kit
in Phase 1 of screening. Some participants didn’t complete the
screening process; of 3105 people with ‘weak-positive’ test results
in Phase 1, 217 (7.0%) failed to complete the screening process (at
either Phase 2 or 3 of screening).
Uptake was high (81.1%) in those who had participated in the
first round with a negative result, whereas for those who did not
respond in the first round it was only 13.1%. In those aged 49–51
years, who were invited for the first time in the second round,
uptake was 44.5%, compared with 51.9% in the same age group in
the first round.
Uptake was also low in new invitees at older ages, 41.5% (522/
1257) in those aged 60 years and over compared with 62.1% in this
age group in the first round. Although the numbers are fairly
small, this is the group most comparable to those to be invited in
the planned roll-out of the screening programme.
Uptake was significantly lower in men than in women (47.7 vs
56.1% Po0.0001), and increased with age, from 45.7% in those
aged under 55 years to 58.5% in those aged 65–69 years. People
aged over 70 years were not invited routinely in the second round,
but were able to request a kit from the screening centre. However,
only 348 people did so, of whom 323 returned an adequate kit. Of
the 323, only 113 were aged between 70 and 71 and so would have
been invited in the first round.
Uptake fell with increasing level of deprivation, from 61.2 to
37.2% in IMD quintiles 1–5 respectively (test for trend Po0.0001),
and was lower in areas with a high proportion of people from the
Indian subcontinent (40.4%) than in areas with a low proportion
(54.0% Po0.000l). These associations remained significant in the
multivariate analysis (Table 1).
Colonoscopy uptake A total of 1171 people had an overall positive
FOBt outcome, of whom 1074 (91.7%). attended for a nurse
appointment and 1001 were recorded as having been referred for
colonoscopy, of whom 970 attended. Uptake of colonoscopy using
number of positive FOBt outcomes as the denominator was 82.8%
(95% CI: 80.6–85.0) in the second round compared with 80.5%
(95% CI: 78.3–82.8) in the first round, but the difference was not
significant (P 0.16). However, some people may have attended for
private colonoscopy, on which we did not have information.
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The positive rate, defined as the rate of a positive FOBt outcome in
those returning an adequate kit, was 1.77%; this was significantly
higher than that of 1.59% in the first round (P 0.01). As observed
in the first round, the positive rate was higher in men than in
women, and increased with age. The positive rate increased
significantly with increasing level of deprivation, and was highest
in areas with a high proportion of people of Indian subcontinent
origin. These effects were reduced but remained significant in the
multivariate analysis.
Detection rates and positive predictive value
The detection rate of cancer was 0.94 per 1000; this was
significantly lower than in the first round (1.35 per 1000, P 0.02).
The detection rate was higher in men (1.40) than women (0.53) and
increased with increasing age. The detection rate of neoplasia
(both cancers and adenomas) was 5.67 per 1000, which was slightly
lower than the first round (6.17 per 1000).
The positive predictive value of a positive FOBt outcome for
cancer was 5.3%, and for all neoplasia was 32.1%. The positive
predictive value for both cancer and neoplasia was significantly
lower than that for the first round (8.5 and 38.8, respectively), but
the difference is restricted to women.
A summary of the screening outcomes for the first and second
round is shown in Table 2.
Interval cancers and sensitivity
There were 98 interval cancers occurring within 2 years of a
negative screen in the first round. The sensitivity of FOBt in
the first round was estimated as 57.7% (95% CI: 48.4–65.6) or
64.4% (95% CI: 56.6–71.1) according to whether England or West
Midlands rates were used to calculate expected incidence in the
absence of screening (Table 3).
This estimate of sensitivity is similar to that of 62.7% observed
in the Nottingham trial (Moss et al, 1999). However, in the Pilot
sensitivity was higher in men than in women and this difference is
in the opposite direction to that observed in the Nottingham trial.
Table 1 Uptake of screening by demographic factors
Uptake
Responded
Number invited n %
Adjusted
OR (95% CI)
Total 127746 66264 51.9
Gender
Male 64373 30711 47.7 1
Female 63373 35553 56.1 1.42 (1.36–1.48)
Gender – age (years)
Male: o55 20016 8275 41.3 1
Male: 55–59 18710 8772 46.9 1.23 (1.18–1.28)
Male: 60–64 14566 7434 51.0 1.47 (1.41–1.54)
Male: 65–69 11081 6230 56.2 1.82 (1.74–1.91)
Female: o55 18967 9528 50.2 1
Female: 55–59 18209 10239 56.2 1.26 (1.20–1.31)
Female: 60–64 14520 8705 60.0 1.49 (1.43–1.56)
Female: 65–69 11677 7081 60.6 1.55 (1.48–1.63)
Deprivation category (IMD)
1 least 19159 11718 61.2 1
2 29266 16923 57.8 0.86 (0.83–0.90)
3 31883 17210 54.0 0.74 (0.72–0.77)
4 26114 12436 47.6 0.60 (0.57–0.62)
5 most 20595 7655 37.2 0.41 (0.39–0.43)
Not known 729 322 44.2
% Indian subcontinent
Quintiles 1–4 (low) 105883 57148 54.0 1
Quintile 5 (high) 19899 8039 40.4 0.89 (0.86–0.93)
Not known 1964 1077 54.8
CI¼confidence interval; IMD¼Index of Multiple Deprivation; OR¼odds ratio.
Table 2 Screening outcomes in first and second rounds of screening
Adequate return
Positive FOBT Cancer Neoplasia PPV of positive test (%) (95% CI)
nn % (95% CI) n Rate per 1000 (95% CI) n Rate per 1000 (95% CI) Cancer Neoplasia
Second round
Gender
Male 30711 665 2.17 (2.01, 2.33) 43 1.40 (1.01, 1.89) 249 8.11 (7.14, 9.18) 6.47 (4.72, 8.61) 37.4 (33.8, 41.2)
Female 35553 506 1.42 (1.30, 1.55) 19 0.53 (0.32, 0.83) 127 3.57 (2.98, 4.25) 3.75 (2.28, 5.80) 25.1 (21.4, 29.1)
Age at entry (years)
o60 36814 538 1.46 (1.34, 1.59) 16 0.43 (0.25, 0.71) 136 3.69 (3.10, 4.37) 2.97 (1.71, 4.78) 25.3 (21.7, 29.2)
60+ 29450 633 2.15 (1.99, 2.32) 46 1.56 (1.14, 2.08) 240 8.15 (7.15, 9.24) 7.27 (5.37, 9.57) 37.9 (34.1, 41.8)
Total 66264 1171 1.77 (1.67, 1.87) 62 0.94 (0.70, 1.17) 376 5.67 (5.12, 6.28) 5.29 (4.08, 6.74) 32.1 (29.4, 34.9)
First round 76152 1211 1.59 (1.50, 1.68) 103 1.35 (1.12, 1.64) 470 6.17 (5.62, 6.74) 8.51 (7.15, 10.40) 38.8 (36.0, 41.5)
CI¼confidence interval.
Table 3 Test sensitivity, interval cancers, and person-years of observation
within the 2-year period following the first round, by gender and age at entry
England West Midlands
Person-
years
Observed
interval
cancers
Rate
per
1000
Expected
cancers
%
detected
by
screen
Expected
cancers
%
detected
by
screen
Gender
Male 100626 49 0.49 140.5 65.1 169.0 71.0
Female 116925 49 0.42 91.0 46.2 106.1 53.4
Age at entry (years)
o60 126346 36 0.28 75.2 52.1 91.9 60.8
60+ 91205 62 0.68 156.2 60.3 183.2 66.2
Total 217551 98 0.45 231.5 57.7 275.1 64.4
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Our assessment of impact of screening on diagnostic and
treatment services was based on procedures directly attributable
to Pilot activity and comparisons with overall activity. Workload
data generated in the first and second rounds of the screening Pilot
(excluding surveillance colonoscopies), for people aged 50–69
years and 60–69 years, are shown in Table 4. There was no decline
in colonoscopy activity in the second round. Further, screening-
associated activity in the two main hospitals associated with the
Pilot increased overall workload by approximately 14 and 28%
respectively which was similar to the first round (Weller et al,
2006). In the second round there were fewer surgical operations
and fewer bowel resection specimens to be examined in pathology
departments; there was also less demand for radiology services
(principally double-contrast barium enema).
Qualitative data from semi-structured interviews revealed a
number of consistent themes. Firstly, the impact was felt most
acutely among staff in endoscopy units; managing and performing
screening-generated surveillance colonoscopies in a timely manner
while meeting the demand for diagnostic work (both Pilot and
non-Pilot) was challenging.
Secondly, for pathology services, the additional work created by
the screening Pilot had most impact in the already overstretched
and understaffed laboratories, although pathology staff were able
to accommodate the extra workload. Finally, personnel involved in
the provision of surgical services were aware of screening patients
increasing their workload and the costs involved in terms of
increased waiting times for non-urgent patients and the provision
of extra operating and staging services. Further details of health
service impact appear in the full report of the Pilot second round
evaluation (Weller et al, 2006).
DISCUSSION
This analysis of the second round of the English Pilot has provided
the opportunity of examining how screening could potentially
operate beyond the prevalence round as the programme becomes
established in the UK. The dynamics of ongoing/periodic screening
are different to those of a one-off prevalence type screen.
A key finding was the lower uptake of screening in the second
round. The reasons for this are unclear; recruitment strategies
were similar in both rounds, although there was greater publicity
when the Pilot was launched, and this may have raised awareness.
It is a form of screening, which is potentially distasteful, and
requires considerable effort on the part of invitees – this may affect
on-going participation. Consideration will need to be given in the
roll-out process to devising ways of maintaining interest and
motivation in a population, which is asked to participate in this
form of screening every 2 years. It is also worth noting that other
forms of FOBt such as immunochemical tests are available and
may be easier to use (Young et al, 2002): the potential of such tests
to produce higher levels of uptake warrants further exploration.
The findings also reinforce the need to devise strategies to address
low uptake in the subgroups which we identified. It would appear
that low levels of uptake persist beyond the first round of screening
in more or less the same pattern, and this will be an important
consideration in reducing health inequalities in colorectal cancer
incidence and outcomes (Smith et al, 2006).
The low number of people over age 70 who requested a kit is not
unexpected, but consideration will need to be given to information
needs for this age group as the Bowel Cancer Screening
Programme rolls out; in the elderly it is especially important to
weight the potential for harm from screening against the likelihood
of benefit, given shorter life expectancy and greater comorbidity
(Ko and Sonnenberg, 2005).
We have compared the positive rates in the Pilot with those of
the first two rounds of the Nottingham trial, restricting both
populations by age and uptake at first round to be comparable
(Weller et al, 2006). The positive rate in the first round of the Pilot
was slightly higher than that in the Nottingham trial (1.61 vs
1.38%). In Nottingham, the rate fell to 0.84% in the second round;
the higher than expected overall positive FOBt outcome rate in the
second round of the Pilot (1.8%) is therefore a cause for some
concern. Clearly, the FOBt positive rate is the main driver for the
rates of colonoscopy, and this is one of the key workforce/capacity
issues in FOBt screening.
There was a drop-off in cancers detected in the second round,
which is not unexpected in an ‘incidence’ versus ‘prevalence’ round
of screening. The detection rate for all neoplasia (both cancers and
adenomas) remained stable. Increasing positive rates coupled with
falling cancer detection rates inevitably means that the predictive
value for cancer of a positive test result is lower than in the first
round. Positive predictive value is one of the most important
markers in screening programmes; high rates of false positives lead
to large numbers of unnecessary investigations being undertaken.
Ultimately, this has an effect on cost effectiveness of screening
(Pignone, 2005), and it will be important to monitor closely trends
in positive rates over time as the programme rolls out; we have
demonstrated that rates can vary considerably.
It will be particularly important to ensure adequate capacity in
endoscopy units as the screening programme rolls out over the
next several years (Tappenden et al, 2007). The colonoscopy rate
per total invited population was similar in both the first and
second round as although the positivity rate increased in round 2,
the uptake of screening was lower. Importantly, the anticipated fall
in demand for initial screening colonoscopies in the second round
did not materialise, and our qualitative data further emphasise the
impact of screening in endoscopic units. Colonoscopy services are
frequently struggling to meet demand for symptomatic referrals.
The Bowel Cancer Screening Programme has decided to bring
management of screening surveillance colonoscopies into the
screening programme; while this will not reduce the number of
colonoscopies required, it will reduce the administrative work in
the endoscopy units and enable the impact of the surveillance
workload to be more clearly determined. There is on-going
uncertainty over optimal colonoscopy intervals for adenoma/polyp
surveillance (Mathew et al, 2006) and there is a need for more
Table 4 Summary of Pilot workload figures for ages 50–69 years for first and second rounds
Population
a
Initial screening
colonoscopies
Biopsy or polyp
specimens
Resections
specimens Operations DCBEs
nn Rate per 100000 n Rate per 100000 n Rate per 100000 n Rate per 100000 n Rate per 100000
First round 124586 1006 807 1150 923 93 75 96 77 61 49
Second round 124477 1026 824 1271 1021 59 47 59 47 38 31
DCBE¼double-contrast barium enema; PCT¼Primary Care Trust.
aThe ‘denominator’ populations for these data are similar to the underlying populations used in Tables 1–3,
except that they include people who were randomised to a trial of an alternative immunological test, and exclude invitees from two practices in South Warwickshire PCT and
people aged 49 at invitation.
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generated surveillance is to be well planned, and incorporated into
existing services.
England, Scotland and Wales are among the first countries in
the world to introduce national programmes for colorectal
screening. Our results suggest that on-going effort will be required
to minimise inequalities in uptake by targeting deprived and
certain ethnic groups, and to ensure adequate capacity –
particularly in the provision of endoscopy services. It will be
important to monitor performance measures such as uptake and
positivity in this ‘roll-out’ phase, as these will give the first
indication of the likely success of the programmes.
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